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Objectives: Carbapenem-resistant Enterobacteriaceae isolates (n¼1485) were received at the French Associated
National Reference Center for Antibiotic Resistance in 2012 and were characterized for their mechanism of resist-
ance to carbapenems.
Methods: Carbapenemase productionwas detected using the biochemical-based CarbaNP test, based on the de-
tection of in vitro hydrolysis of imipenem. All isolateswith a positive CarbaNP test result were characterized by PCR
and sequencing.
Results: Carbapenemase production was identiﬁed in 23.1% of the isolates. The main carbapenemase type
identiﬁed was OXA-48 and derivatives (75.5%). An overseas source was clearly demonstrated for only 27.6% of
the isolates.
Conclusions: OXA-48 and derivatives are now the most prevalent carbapenemases in France, with a possible
spread of these producers in the community.
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Introduction
During the last decade, Gram-negative clinical isolates, including
Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp.
with decreased susceptibility to carbapenems, have been increas-
ingly reported in Europe.1,2 Carbapenem resistance in Enterobac-
teriaceae may be related either to the association of a decrease
in bacterial outer-membrane permeability with overexpression of
b-lactamases possessing a very weak carbapenemase activity, or
to a b-lactamase with strong hydrolytic activity towards carbape-
nems, i.e. a carbapenemase.2Differentiationof thesemechanisms
may have consequences for the clinical management of patients
and prevention of nosocomial outbreaks.3–5 Themain carbapene-
mases described in Enterobacteriaceae are the Ambler class A KPC
enzymes,6 Ambler class B b-lactamases (metallo-b-lactamases)
of VIM, IMP and NDM types,2,7 and Ambler class D carbapenemases
of theOXA-48type.8Thecarbapenemase-producingEnterobacteria-
ceaeareusually resistanttomanyotherb-lactamandnon-b-lactam
antibiotics, giving rise to multiresistant and pandrug-resistant
isolates.
Methods
From January 2012 to December 2012, 1485 enterobacterial isolates were
received from all areas of France by the French Associated National Refer-
enceCenter for Antibiotic Resistance in order to test for carbapenemaseac-
tivity leading to reduced susceptibility to carbapenems. All isolates were
identiﬁed at the species level using a MALDI-TOF spectrometric identiﬁca-
tion system (bioMe´rieux, La Balme-les-Grottes, France). Most of them
wereEnterobacter spp. (42.2%),Klebsiellapneumoniae (35.2%)andEscher-
ichia coli (12.7%). Susceptibilities to antibiotics, including carbapenems,
aminoglycosides, quinolones, tigecycline, fosfomycin, co-trimoxazole,
chloramphenicol and nitrofurantoin, were determined by disc diffusion on
Mueller–Hinton agar (Bio-Rad, Marnes-la-Coquette, France). According to
EUCAST breakpoints (www.eucast.org), most of the isolates were non-
susceptible to at least one of the three carbapenems for which MICs were
determined by Etest (bioMe´rieux) (imipenem, meropenem and ertapen-
em). Carbapenemase production was detected using the Carba NP test,
based on the detection of in vitro hydrolysis of imipenem demonstrated
by a chromogenic test.9 All isolates giving a positive Carba NP test result
were characterized by PCR aimed at identifying the main carbapenemase












which should be cited to refer to this work.
Table 1. Geographical origins of carbapenemase-producing isolates
Carbapenemase type
OXA-48 OXA-162 OXA-181 OXA-204 KPC-2 KPC-3 NDM-1 NDM-4 NDM-5 NDM-7 VIM-1 VIM-2 VIM-4 IMI-1 IMI-2
Morocco 17

























56 (22.6) 1 (33.3) 2 (100) 0 (0) 5 (20.8) 3 (20.0) 16 (76.2) 3 (75.0) 1 (100) 1 (100) 3 (42.9) 0 (0) 3 (100) 0 (0) 0 (0)
Unknown or no linkage
with foreign country (%)
192 (77.4) 2 (66.7) 0 (0) 4 (100) 19 (79.2) 12 (80.0) 5 (23.8) 1 (25.0) 0 (0) 0 (0) 4 (57.1) 6 (100) 0 (0) 1 (100) 1 (100)












































































































































Figure 1. Distribution of enterobacterial species of carbapenemase-producing (+) and non-carbapenemase-producing (2) isolates. (Left) Distribution of
OXA-48-like,NDM,KPC,VIMandIMIcarbapenemases foreachgroupofenterobacterial species. (Middle)Distributionofcarbapenemase-producing (+) and
non-carbapenemase-producing (2) isolates inenterobacterial species. (Right)Distributionofnon-carbapenemasemechanisms responsible fordecreased
carbapenem susceptibility in enterobacterial species: impermeability (imp), ESBL+ impermeability, cephalosporinase (Case)+ impermeability and
ESBL+cephalosporinase+ impermeability. Carbapenem-susceptible isolates (after MIC conﬁrmation) are also shown. Numbers correspond to the











and blaOXA-48. PCR amplicons were subsequently sequenced.
3 Decreased
carbapenem susceptibility due to overexpression of a cephalosporinase
(chromosome encoded or plasmid acquired) was suspected for
isolates (i) having carbapenem susceptibility restored on cloxacillin-
supplemented (200 mg/L) Mueller–Hinton agar and (ii) being negative
in the Carba NP test. Additionally, growth on cloxacillin-supplemented
medium led to the detection of extended-spectrumb-lactamase (ESBL)-
producing isolates that also produce a cephalosporinase at a high level.
ESBL production was demonstrated by double disc synergy testing
between extended-spectrum cephalosporins (cefotaxime, ceftazidime,
cefepime and aztreonam) and clavulanate (ticarcillin/clavulanic acid),
performed on Mueller–Hinton agar and cloxacillin-supplemented
Mueller–Hinton agar.
Results
Among the1485 tested isolates, 341 (22.9%)producedacarbape-
nemase. These carbapenemases were OXA-48 like (75.4%), KPC
(11.4%), NDM (7.9%), VIM (4.7%) and IMI (0.6%) (Table 1). Most
of the carbapenemase producers were K. pneumoniae isolates
(65.9%), which are mostly nosocomial pathogens. Additionally,
another group of nosocomial pathogens, Enterobacter species,
represented 9.7% of the carbapenemase producers. Therefore,
the spread of carbapenemase-producing Enterobacteriaceae
was mainly associated with hospital dissemination in France.
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Figure 2. (a) Determination of linkagewith a cross-border country for patients infected or colonizedwith carbapenemase-producing Enterobacteriaceae.











carbapenemase producers (15.5%). Since their nosocomial acqui-
sition could not be clearly established, dissemination of these
strains in the community remains possible. All carbapenemase
producers expressed a single carbapenemase type except one
isolate of K. pneumoniae that was positive for NDM-1 and
OXA-181 (an OXA-48 variant). Regardless of the enterobacterial
species, OXA-48-like carbapenemases were predominant (76.8%
of carbapenemase-producing K. pneumoniae, 81.1% of
carbapenemase-producing E. coli, 75.8% of carbapenemase-
producing Enterobacter spp., 53.3% of carbapenemase producers
among the other enterobacterial species) (Figure 1). Like OXA-48
producers, NDM producers were equally distributed among the
groups of bacterial species (P.0.05, x2 test) (Figure 1). Conversely,
KPC producers (95%, P,0.001, x2 test) were signiﬁcantly more
represented inK. pneumoniae comparedwith theotherenterobac-
terial species (37 K. pneumoniae, 1E. coliand1Citrobacter freundii).
The main species associated with VIM carbapenemases was C.
freundii (62.5%), but this result is biased by the clonal dissemin-
ation of a single VIM-positive isolate in the same hospital. The
IMI producers (n¼2) were Enterobacter spp. (1 Enterobacter
asburiae and 1 Enterobacter cloacae).
In the absence of carbapenemase production, the decreased
susceptibility to carbapenems was explained by decreased outer
membrane permeability associated with the expression of a
b-lactamase with weak hydrolytic activity against carbapenems.
ESBL production was mostly detected in K. pneumoniae (75.2%)
and E. coli (66.7%), whereas, as expected, overexpression of the
chromosome-encoded cephalosporinase was mainly involved in
Enterobacter spp. (68.2%) (Figure 1).
A probable linkwith a foreign countrywas established for 27.6%
(94/341) of patients infected or colonized with a carbapenemase
producer (Table 1). This link with a cross-border country was
clearly identiﬁed for NDM producers (Table 1). Indeed, most of the
NDM-producing isolates (77.8%) were related to the Indian sub-
continent, which is known to be the main reservoir of metallo-
b-lactamase.7 Of note, several strains were isolated on Re´union
island, indicating that this French territory (near to Madagascar)
is the most exposed for NDM dissemination. The KPC-producing
strains were often recovered from patients previously hospitalized
in Italyand Israel, twocountrieswhereKPCproducersarewidelydis-
seminated.6 Curiously, despite the economic and social relation-
ships between Greece and France, no KPC-producing isolate was
recovered frompatients having linkswith Greece, where KPC produ-
cers are endemic. Of the 56 OXA-48 producers with an established
link with a foreign country, 48 (85.7%) were related to North
African countries, and all OXA-181 producers were related to
India. These results are in agreement with the epidemiological
data known about OXA-48 and its variants.8,10 The fact that
OXA-48 and derivatives are now the most prevalent carbapene-
mases in France is related to the large population exchange with
NorthAfricancountries.However, aclear linkagewithacross-border
country has been reported for only 29.9%ofOXA-48-like producers,
indicating a possible spread of OXA-48 producers in the community
in France.
Among the 341 carbapenemase-producing isolates, 204
(59.8%) were isolated from rectal swabs and 137 (40.2%) were
from clinical samples (Figure 2). These percentages were similar
for all carbapenemase types. Of note, 43.1% (97/225) of the
carbapenemase-producing K. pneumoniae were from clinical
samples. This frequency was signiﬁcantly higher (P,0.05, Stu-
dent’s t-test) than that observed for carbapenemase-producing
E. coli (28.3%).
Discussion
Carbapenem resistance in Enterobacteriaceae isolates from
France has been increasing since 2005 (data not shown). Analysis
of 1485 carbapenem-resistant isolates isolated in 2012 high-
lighted several concerns. (i) The two main organisms with
decreased susceptibility to carbapenems are K. pneumoniae and
Enterobacter spp. However, a major difference was observed
between these two groups: 43% of K. pneumoniae isolates
produced a carbapenemase, whereas only 5.3% of Enterobacter
spp. did so. (ii) The main carbapenemase identiﬁed was OXA-48,
which could be linked in part to dissemination in the community.
The Carba NP test has been shown to be a powerful technique
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